Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
new option listings and one option delisting on March 10th » 08:30
03/10/21
03/10
08:30
03/10/21
08:30
BWAC

Better World Acquisition

$9.99 /

+0.03 (+0.30%)

, CONX

Conx

$10.03 /

-0.08 (-0.79%)

, DCRB

Decarbonization Plus Acquisition

$11.30 /

+0.5 (+4.63%)

, DMYI

dMY Technology Group, Inc. III

$11.31 /

+0.41 (+3.76%)

, GHVI

Gores Holdings VI

$15.94 /

+1.3 (+8.88%)

, GNRS

Greenrose Acquisition

$10.04 /

+ (+0.00%)

, HAAC

Health Assurance Acquisition

$10.63 /

+0.14 (+1.33%)

, HZON

Horizon Acquisition Corp. II

$10.88 /

+0.01 (+0.09%)

, IACA

Ion Acquisition 1

$10.94 /

+0.15 (+1.39%)

, IGAC

IG Acquisition

$9.96 /

+0.04 (+0.40%)

, LCY

Landcadia Holdings III

$10.40 /

+ (+0.00%)

, LEAP

Ribbit LEAP

$11.96 /

+0.35 (+3.01%)

, LFTR

Lefteris Acquisition

$10.21 /

+0.01 (+0.10%)

, LUXA

Lux Health Tech Acquisition

$10.57 /

+0.06 (+0.57%)

, MCMJ

Merida Merger Corp. I

$10.09 /

+0.115 (+1.15%)

, ONCR

Oncorus

$14.78 /

+0.72 (+5.12%)

, PIPP

Pine Island Acquisition

$10.39 /

+0.07 (+0.68%)

, RAAC

Revolution Acceleration Acquisition Corp

$10.51 /

-0.04 (-0.38%)

, RMGB

RMG Acquisition Corporation II

$10.31 /

-0.13 (-1.25%)

, SEAH

Sports Entertainment Acquisition

$10.01 /

+0.01 (+0.10%)

, SPNV

Supernova Partners Acquisition

$10.30 /

+0.09 (+0.88%)

, SYPR

Sypris Solutions

$3.26 /

+0.16 (+5.16%)

, TWCT

TWC Tech Holdings II

$10.02 /

-0.085 (-0.84%)

, WPF

Foley Trasimene Acquisition Corp.

$10.20 /

+0.065 (+0.64%)

, XPOA

DPCM Capital

$10.12 /

-0.07 (-0.69%)

, YALA

Yalla

$19.49 /

+1.57 (+8.76%)

, NK

NantKwest

$0.00 /

+ (+0.00%)

New option listings for…

New option listings for March 10th include Burgundy Technology Acquition Corporation (Class A Stock) (BTAQ), Better World Acquisition Corporation (BWAC), CONX Corporation (Class A Stock) (CONX), Decarbonization Plus Acquisition Corporation (Class A Stock) (DCRB), dMY Technology Group Inc III (Class A Stock) (DMYI), FG New America Acquisition Corp (Class A Stock) (FGNA), FirstMark Horizon Acquisition Corp (Class A Stock) (FMAC), Gores Holdings VI Inc (Class A Stock) (GHVI), Greenrose Axquisition Corporation (GNRS), Health Assurance Acquisition Corporation (Class A Stock) (HAAC), Horizon Acquisition Corporation II (Class A Stock) (HZON), ION Acquisition Corp 1 Ltd (Class A Stock) (IACA), ImmunityBio Inc (IBRX), IG Acquisition Corporation (Class A Stock) (IGAC), Landcadia Holdings III Inc (Class A Stock) (LCY), Ribbit LEAP Ltd (Class A Stock) (LEAP), Lefteris Acquisition Corporation (Class A Stock) (LFTR), Lux Health Tech Acquisition Corporation (Class A Stock) (LUXA), Merida Merger Corporation I (MCMJ), Oncorus Inc (ONCR), Pine Island Acquisition Corp (Class A Stock) (PIPP), Revolution Acceleration Acquisition Corporation (Class A Stock) (RAAC), RMG Acquisition Corporation II (Class A Stock) (RMGB), Sports Entertainment Acquisition Corp (Class A Stock) (SEAH), Supernova Partners Acquisition Company Inc (Class A Stock) (SPNV), Sypris Solutions (SYPR), Main Thematic Innovation (TMAT), TS Innovation Acquisition Corporation (Class A Stock) (TSIA), TWC Tech Holdings II Corporation (TWCT), Foley Trasimene Acquisition Corp (Class A Stock) (WPF), DPCM Capital Inc (Class A Stock) (XPOA), and Yalla Group Limited (Class A ADS) (YALA). Option delistings effective March 10th include NantKwest Inc (NK).

ShowHide Related Items >><<
YALA Yalla
$19.49 /

+1.57 (+8.76%)

WPF Foley Trasimene Acquisition Corp.
$10.20 /

+0.065 (+0.64%)

SYPR Sypris Solutions
$3.26 /

+0.16 (+5.16%)

RMGB RMG Acquisition Corporation II
$10.31 /

-0.13 (-1.25%)

RAAC Revolution Acceleration Acquisition Corp
$10.51 /

-0.04 (-0.38%)

ONCR Oncorus
$14.78 /

+0.72 (+5.12%)

NK NantKwest
$0.00 /

+ (+0.00%)

LCY Landcadia Holdings III
$10.40 /

+ (+0.00%)

IACA Ion Acquisition 1
$10.94 /

+0.15 (+1.39%)

HZON Horizon Acquisition Corp. II
$10.88 /

+0.01 (+0.09%)

GHVI Gores Holdings VI
$15.94 /

+1.3 (+8.88%)

DMYI dMY Technology Group, Inc. III
$11.31 /

+0.41 (+3.76%)

DCRB Decarbonization Plus Acquisition
$11.30 /

+0.5 (+4.63%)

BWAC Better World Acquisition
$9.99 /

+0.03 (+0.30%)

CONX Conx
$10.03 /

-0.08 (-0.79%)

DCRB Decarbonization Plus Acquisition
$11.30 /

+0.5 (+4.63%)

DMYI dMY Technology Group, Inc. III
$11.31 /

+0.41 (+3.76%)

GHVI Gores Holdings VI
$15.94 /

+1.3 (+8.88%)

GNRS Greenrose Acquisition
$10.04 /

+ (+0.00%)

HAAC Health Assurance Acquisition
$10.63 /

+0.14 (+1.33%)

HZON Horizon Acquisition Corp. II
$10.88 /

+0.01 (+0.09%)

IACA Ion Acquisition 1
$10.94 /

+0.15 (+1.39%)

IGAC IG Acquisition
$9.96 /

+0.04 (+0.40%)

LCY Landcadia Holdings III
$10.40 /

+ (+0.00%)

LEAP Ribbit LEAP
$11.96 /

+0.35 (+3.01%)

LFTR Lefteris Acquisition
$10.21 /

+0.01 (+0.10%)

LUXA Lux Health Tech Acquisition
$10.57 /

+0.06 (+0.57%)

MCMJ Merida Merger Corp. I
$10.09 /

+0.115 (+1.15%)

ONCR Oncorus
$14.78 /

+0.72 (+5.12%)

11/11/20 Piper Sandler
Oncorus timelines remain on track after Q3 results, says Piper Sandler
10/27/20 Jefferies
Oncorus initiated with a Buy at Jefferies
10/27/20 Evercore ISI
Oncorus initiated with an Outperform at Evercore ISI
10/27/20 Piper Sandler
Oncorus initiated with an Overweight at Piper Sandler
PIPP Pine Island Acquisition
$10.39 /

+0.07 (+0.68%)

RAAC Revolution Acceleration Acquisition Corp
$10.51 /

-0.04 (-0.38%)

RMGB RMG Acquisition Corporation II
$10.31 /

-0.13 (-1.25%)

SEAH Sports Entertainment Acquisition
$10.01 /

+0.01 (+0.10%)

SPNV Supernova Partners Acquisition
$10.30 /

+0.09 (+0.88%)

SYPR Sypris Solutions
$3.26 /

+0.16 (+5.16%)

TWCT TWC Tech Holdings II
$10.02 /

-0.085 (-0.84%)

WPF Foley Trasimene Acquisition Corp.
$10.20 /

+0.065 (+0.64%)

XPOA DPCM Capital
$10.12 /

-0.07 (-0.69%)

YALA Yalla
$19.49 /

+1.57 (+8.76%)

12/10/20 Oppenheimer
Yalla initiated with a Perform on valuation at Oppenheimer
12/10/20 Oppenheimer
Yalla initiated with a Perform at Oppenheimer
10/26/20 Morgan Stanley
Yalla initiated with an Equal Weight at Morgan Stanley
NK NantKwest
$0.00 /

+ (+0.00%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
ONCR Oncorus
$14.78 /

+0.72 (+5.12%)

  • 12
    Feb
  • 02
    Oct
  • 30
    Sep
  • 25
    Jun
XPOA DPCM Capital
$10.12 /

-0.07 (-0.69%)

SPNV Supernova Partners Acquisition
$10.30 /

+0.09 (+0.88%)

LEAP Ribbit LEAP
$11.96 /

+0.35 (+3.01%)

LCY Landcadia Holdings III
$10.40 /

+ (+0.00%)

HZON Horizon Acquisition Corp. II
$10.88 /

+0.01 (+0.09%)

GHVI Gores Holdings VI
$15.94 /

+1.3 (+8.88%)

DMYI dMY Technology Group, Inc. III
$11.31 /

+0.41 (+3.76%)

DCRB Decarbonization Plus Acquisition
$11.30 /

+0.5 (+4.63%)

PIPP Pine Island Acquisition
$10.39 /

+0.07 (+0.68%)

NK NantKwest
$0.00 /

+ (+0.00%)

LEAP Ribbit LEAP
$11.96 /

+0.35 (+3.01%)

LCY Landcadia Holdings III
$10.40 /

+ (+0.00%)

IACA Ion Acquisition 1
$10.94 /

+0.15 (+1.39%)

HZON Horizon Acquisition Corp. II
$10.88 /

+0.01 (+0.09%)

GHVI Gores Holdings VI
$15.94 /

+1.3 (+8.88%)

DCRB Decarbonization Plus Acquisition
$11.30 /

+0.5 (+4.63%)

CONX Conx
$10.03 /

-0.08 (-0.79%)

BWAC Better World Acquisition
$9.99 /

+0.03 (+0.30%)

Hot Stocks
NantKwest stockholders approve merger with ImmunityBio » 16:31
03/08/21
03/08
16:31
03/08/21
16:31
NK

NantKwest

$28.17 /

+1.27 (+4.72%)

NantKwest announced that…

NantKwest announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special meeting of stockholders held earlier in the day, including approval of the merger by a majority of unaffiliated stockholders of NantKwest. The merger is expected to close on March 9, 2021, subject to the satisfaction of customary closing conditions. Following the closing of the transaction, the combined company will assume the ImmunityBio name and its shares of common stock are expected to trade on NASDAQ under the symbol "IBRX" commencing on March 10, 2021.

ShowHide Related Items >><<
NK NantKwest
$28.17 /

+1.27 (+4.72%)

NK NantKwest
$28.17 /

+1.27 (+4.72%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$28.17 /

+1.27 (+4.72%)

Hot Stocks
NantKwest, ImmunityBio begin dosing patients in COVID-19 vaccine candidate trial » 09:08
03/08/21
03/08
09:08
03/08/21
09:08
NK

NantKwest

$26.78 /

+1.1202 (+4.37%)

ImmunityBio and NantKwest…

ImmunityBio and NantKwest announced the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the company's T-cell-based COVID-19 vaccine candidate, hAd5. This candidate is unique in targeting both the spike and nucleocapsid proteins of the SARS-CoV-2 virus. These trials will determine which route combination provides the strongest immune response and long-term immunity, as well as the vaccine candidate's effectiveness against the growing number of mutated variants of the virus. In the three trials, the hAd5 vaccine candidate is being administered in a subcutaneous, oral, or sublingual formulation. The Phase I trial in Cape Town, South Africa is using subcutaneous administration and nine participants have been dosed to date. It is expected to be followed by sublingual delivery and room temperature-stable oral capsule trials. The two U.S. Phase Ib trials are studying a combination of subcutaneous/sublingual and subcutaneous/oral formulations; six participants have been dosed in each trial to date. In total, 140 participants will be enrolled in the South African and U.S. trials.

ShowHide Related Items >><<
NK NantKwest
$26.78 /

+1.1202 (+4.37%)

NK NantKwest
$26.78 /

+1.1202 (+4.37%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$26.78 /

+1.1202 (+4.37%)

On The Fly
Fly Intel: Pre-market Movers » 09:05
02/12/21
02/12
09:05
02/12/21
09:05
XERS

Xeris Pharmaceuticals

$6.63 /

-0.575 (-7.99%)

, NK

NantKwest

$26.00 /

-0.32 (-1.22%)

, INO

Inovio

$13.00 /

+ (+0.00%)

, DIS

Disney

$190.80 /

+1.19 (+0.63%)

, HUBS

HubSpot

$431.81 /

+7.985 (+1.88%)

, NWL

Newell Brands

$26.05 /

-0.15 (-0.57%)

, LLNW

Limelight Networks

$4.56 /

-0.08 (-1.72%)

, PLX

Protalix

$5.72 /

-0.005 (-0.09%)

, CDAK

Codiak

$24.62 /

+0.52 (+2.16%)

, SPCE

Virgin Galactic

$59.50 /

+7.18 (+13.72%)

, FUSE

Fusion Acquisition

$12.30 /

+0.54 (+4.59%)

Check out this morning's…

ShowHide Related Items >><<
XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

PLX Protalix
$5.72 /

-0.005 (-0.09%)

NK NantKwest
$26.00 /

-0.32 (-1.22%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

FUSE Fusion Acquisition
$12.30 /

+0.54 (+4.59%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

CDAK Codiak
$24.62 /

+0.52 (+2.16%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

08/20/20 Mizuho
Mizuho sees no material impact to Xeris following FDA letter about advertising
04/23/20 Mizuho
Xeris Pharmaceuticals price target lowered to $14 from $18 at Mizuho
02/20/20 Mizuho
Xeris Pharmaceuticals price target lowered to $18 from $22 at Mizuho
02/18/20
Fly Intel: Top five analyst initiations
NK NantKwest
$26.00 /

-0.32 (-1.22%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
INO Inovio
$13.00 /

+ (+0.00%)

02/11/21 Oppenheimer
Opco starts DNA medicines 'disruptor' Inovio with buy, $35 price target
02/11/21 Oppenheimer
Inovio initiated with an Outperform at Oppenheimer
02/09/21 Maxim
Heat data puts cancer vaccine discussion 'back on the table,' says Maxim
01/08/21 Benchmark
Inovio price target lowered to $15 from $25 at Benchmark
DIS Disney
$190.80 /

+1.19 (+0.63%)

02/12/21 Loop Capital
Disney price target raised to $230 from $190 at Loop Capital
02/12/21 Evercore ISI
Disney price target raised to $210 from $200 at Evercore ISI
02/12/21 JPMorgan
Disney price target raised to $220 from $210 at JPMorgan
02/12/21 Credit Suisse
Disney price target raised to $218 from $192 at Credit Suisse
HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

02/12/21 Needham
HubSpot price target raised to $520 from $400 at Needham
02/12/21 Cowen
HubSpot price target raised to $510 from $400 at Cowen
02/12/21 Raymond James
HubSpot upgraded to Strong Buy from Outperform at Raymond James
02/12/21 Truist
HubSpot price target raised to $600 from $455 at Truist
NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

02/04/21 Deutsche Bank
Newell Brands price target raised to $23 from $18 at Deutsche Bank
01/08/21 BofA
Newell Brands upgraded to Buy on shift away from home at BofA
01/08/21 BofA
Newell Brands upgraded to Buy from Neutral at BofA
01/04/21 Jefferies
Jefferies upgrades 'underappreciated' Newell Brands to Buy from Hold
LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

02/12/21 Lake Street
Limelight Networks price target lowered to $6 from $9 at Lake Street
02/12/21 DA Davidson
Limelight Networks downgraded to Underperform from Neutral at DA Davidson
02/12/21 Raymond James
Limelight Networks downgraded to Market Perform from Outperform at Raymond James
02/12/21 Truist
Limelight Networks downgraded to Hold from Buy at Truist
PLX Protalix
$5.72 /

-0.005 (-0.09%)

12/31/20 H.C. Wainwright
Protalix data underscore value proposition for PRX-102, says H.C. Wainwright
CDAK Codiak
$24.62 /

+0.52 (+2.16%)

12/31/20 Wedbush
Codiak price target raised to $31 from $19 at Wedbush
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Wedbush
Codiak initiated with an Outperform at Wedbush
11/08/20 Goldman Sachs
Codiak initiated with a Buy at Goldman Sachs
SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

02/09/21 UBS
Virgin Galactic downgraded to Neutral from Buy at UBS
02/01/21
Fly Intel: Top five analyst downgrades
02/01/21 Morgan Stanley
Morgan Stanley downgrades Virgin Galactic to Equal Weight, sees 35% downside
02/01/21 Morgan Stanley
Virgin Galactic downgraded to Equal Weight from Overweight at Morgan Stanley
FUSE Fusion Acquisition
$12.30 /

+0.54 (+4.59%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

CDAK Codiak
$24.62 /

+0.52 (+2.16%)

  • 12
    Feb
  • 12
    Feb
  • 21
    Jan
  • 14
    Oct
  • 06
    Aug
  • 25
    Jun
  • 26
    Jun
  • 03
    Jun
  • 20
    May
SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

NK NantKwest
$26.00 /

-0.32 (-1.22%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

HUBS HubSpot
$431.81 /

+7.985 (+1.88%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

CDAK Codiak
$24.62 /

+0.52 (+2.16%)

XERS Xeris Pharmaceuticals
$6.63 /

-0.575 (-7.99%)

SPCE Virgin Galactic
$59.50 /

+7.18 (+13.72%)

NWL Newell Brands
$26.05 /

-0.15 (-0.57%)

LLNW Limelight Networks
$4.56 /

-0.08 (-1.72%)

INO Inovio
$13.00 /

+ (+0.00%)

FUSE Fusion Acquisition
$12.30 /

+0.54 (+4.59%)

DIS Disney
$190.80 /

+1.19 (+0.63%)

Hot Stocks
NantKwest, ImmunityBio say FDA authorizes expansion of COVID vaccine testing » 18:14
02/11/21
02/11
18:14
02/11/21
18:14
NK

NantKwest

$26.00 /

-0.32 (-1.22%)

ImmunityBio and NantKwest…

ImmunityBio and NantKwest announced they have received FDA authorization to expand Phase I testing of a bivalent hAd5 T-cell COVID-19 vaccine. The FDA authorized the expansion of a currently active multi-cohort trial of the subcutaneous version of the vaccine in order to study the addition of sublingual boosts. The FDA also authorized a second Phase I study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants in the U.S. trials of their vaccine candidate, which is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. The expectations of inducing protective immune responses in healthy volunteers - with this novel combination of an oral boost with a subcutaneous prime - are based on the positive findings reported in the NIH/BARDA-sponsored Non-Human Primate (NHP) study. This recent data showed that when administered with an oral boost, the bivalent vaccine resulted in potent stimulation of S- and N-specific T cells with potent antibody release from memory B cells following viral challenge. Additionally, activation of the full immune system by S and N proteins resulted in complete viral clearance of SARS-CoV-2 in lung and nasal passages following the challenge. On the basis of these findings, ImmunityBio has expanded the current Phase 1 study of subcutaneous prime with oral or sublingual boost to explore the potential of this second-generation vaccine to reduce disease and transmission of the virus.

ShowHide Related Items >><<
NK NantKwest
$26.00 /

-0.32 (-1.22%)

NK NantKwest
$26.00 /

-0.32 (-1.22%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$26.00 /

-0.32 (-1.22%)

Hot Stocks
CytRx highlights NantKwest, ImmunityBio clinical trials of immunotherapy » 08:13
01/15/21
01/15
08:13
01/15/21
08:13
CYTR

CytRx

$0.30 /

+ (+0.00%)

, NK

NantKwest

$17.82 /

+3.04 (+20.57%)

CytRx (CYTR) highlighted…

CytRx (CYTR) highlighted that NantKwest (NK) and ImmunityBio have announced that their ongoing Phase 2 clinical trials of a novel combination immunotherapy - which include CytRx's licensed drug aldoxorubicin - for locally advanced or metastatic pancreatic cancer have produced early indications of increased survival rates for patients with no other approved treatment options. Interim results of the three-cohort trials, known as QUILT 88, show median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer.

ShowHide Related Items >><<
NK NantKwest
$17.82 /

+3.04 (+20.57%)

CYTR CytRx
$0.30 /

+ (+0.00%)

CYTR CytRx
$0.30 /

+ (+0.00%)

NK NantKwest
$17.82 /

+3.04 (+20.57%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$17.82 /

+3.04 (+20.57%)

NK NantKwest
$17.82 /

+3.04 (+20.57%)

Hot Stocks
NantKwest up 22% to $18.00 after interim data on cancer trials  18:06
01/13/21
01/13
18:06
01/13/21
18:06
NK

NantKwest

$14.78 /

-1.185 (-7.42%)

 
ShowHide Related Items >><<
NK NantKwest
$14.78 /

-1.185 (-7.42%)

NK NantKwest
$14.78 /

-1.185 (-7.42%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$14.78 /

-1.185 (-7.42%)

NK NantKwest
$14.78 /

-1.185 (-7.42%)

Hot Stocks
NantKwest, ImmunityBio announce early results of PD-L1 t-haNK protocols » 18:04
01/13/21
01/13
18:04
01/13/21
18:04
NK

NantKwest

$14.78 /

-1.185 (-7.42%)

NantKwest and ImmunityBio…

NantKwest and ImmunityBio announced early interim results of its PD-L1 t-haNK protocols showing median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer for which no other FDA-approved treatment exists. These trials, which were based on the original Cancer Moonshot hypothesis and exploratory QUILT trials initiated in 2017, appear to validate the theory that by orchestrating natural killer and T-cell therapy, survival rates could be improved without high-dose chemotherapy.

ShowHide Related Items >><<
NK NantKwest
$14.78 /

-1.185 (-7.42%)

NK NantKwest
$14.78 /

-1.185 (-7.42%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$14.78 /

-1.185 (-7.42%)

NK NantKwest
$14.78 /

-1.185 (-7.42%)

Over a quarter ago
Hot Stocks
CytRx comments on proposed combination of ImmunityBio and NantKwest » 08:10
12/22/20
12/22
08:10
12/22/20
08:10
CYTR

CytRx

$0.30 /

+ (+0.00%)

, NK

NantKwest

$16.02 /

+5.78 (+56.45%)

CytRx (CYTR)…

CytRx (CYTR) congratulated ImmunityBio and NantKwest on their proposed merger and announced plans to create a leading immunotherapy and cell therapy company. CytRx out-licensed global development, manufacturing and commercialization rights for aldoxorubicin to ImmunityBio in 2017. The Company has an agreement with ImmunityBio that can yield up to $343M in potential milestone payments and single and double-digit royalties on sales of aldoxorubicin. In their announcement, ImmunityBio and NantKwest highlighted that the combined entity will have a broad clinical-stage pipeline - including 13 assets in clinical trials and 11 in Phase 2 to 3 programs - as well as a robust early-stage pipeline to address other difficult to treat cancers. The companies also noted that the combination of NantKwest's Natural Killer cell platform and ImmunityBio's immunotherapy platforms - including albumin-based tumor microenvironment immune modulators- have already resulted in complete responses in aggressive and late-stage metastatic cancers. To date, complete responses have been noted in patients with second-line or greater metastatic pancreatic cancer, triple-negative breast cancer, head and neck cancer, and Merkel Cell Carcinoma. Notably, ImmunityBio and NantKwest recently announced the addition of a third cohort to an ongoing Phase 2 study of a novel combination immunotherapy - which includes aldoxorubicin - for locally advanced or metastatic pancreatic cancer (QUILT-88). As previously outlined in CytRx's October 7, 2020 announcement regarding the successful treatment delivered to former Nevada Senator Harry Reid for his stage IV pancreatic cancer, the randomized, open-label study is evaluating the safety and efficacy of a combination immunotherapy that includes aldoxorubicin, ImmunityBio's IL-15 superagonist Anktiva NantKwest's PD-L1 t-haNK and standard of care. The study results will be compared to standard of care chemotherapy for first- and second-line treatment. However, the third-line cohort is a single arm with no comparator and each cohort will be evaluated independently to provide a more precise comparative.

ShowHide Related Items >><<
NK NantKwest
$16.02 /

+5.78 (+56.45%)

CYTR CytRx
$0.30 /

+ (+0.00%)

CYTR CytRx
$0.30 /

+ (+0.00%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
  • 25
    Jun
NK NantKwest
$16.02 /

+5.78 (+56.45%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:39
12/21/20
12/21
16:39
12/21/20
16:39
MRNA

Moderna

$138.24 /

-1.99 (-1.42%)

, PFE

Pfizer

$37.37 /

-0.315 (-0.84%)

, BNTX

BioNTech

$106.36 /

+2.27 (+2.18%)

, LMT

Lockheed Martin

$349.32 /

-6.91 (-1.94%)

, AJRD

Aerojet Rocketdyne

$52.78 /

+10.65 (+25.28%)

, RP

RealPage

$87.27 /

+19.63 (+29.02%)

, NKE

Nike

$143.97 /

+4.93 (+3.55%)

, WBAI

500.com

$3.79 /

+1.135 (+42.75%)

, NK

NantKwest

$16.02 /

+5.78 (+56.45%)

, QURE

uniQure

$38.51 /

-7.39 (-16.10%)

, FGEN

FibroGen

$40.01 /

-3.98 (-9.05%)

The major averages…

ShowHide Related Items >><<
WBAI 500.com
$3.79 /

+1.135 (+42.75%)

RP RealPage
$87.27 /

+19.63 (+29.02%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

12/22/20 Roth Capital
Translate Bio price target raised to $37 from $30 at Roth Capital
12/21/20 SVB Leerink
Moderna price target raised to $69 from $60 at SVB Leerink
12/21/20 Oppenheimer
Moderna price target raised to $178 from $157 at Oppenheimer
12/18/20 Barclays
Moderna price target raised to $169 from $84 at Barclays
PFE Pfizer
$37.37 /

-0.315 (-0.84%)

12/16/20
Fly Intel: Top five analyst downgrades
12/16/20 KeyBanc
Maravai Lifesciences initiated with an Overweight at KeyBanc
12/16/20 RBC Capital
Pfizer downgraded to Sector Perform from Outperform at RBC Capital
BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

12/15/20 Jefferies
Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play'
12/14/20 Citi
Arcturus Therapeutics price target raised to $133 from $62 at Citi
12/08/20 Goldman Sachs
Goldman says FDA briefing documents supportive of approval for Pfizer vaccine
LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

12/22/20 Credit Suisse
Lockheed Martin price target raised to $409 from $400 at Credit Suisse
12/22/20 Truist
Aerojet Rocketdyne downgraded to Hold from Buy at Truist
12/21/20 Canaccord
Boeing not in position to challenge Aerojet bid, says Canaccord
12/21/20 RBC Capital
Aerojet Rocketdyne price target raised to $56 from $51 at RBC Capital
AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

12/21/20 Truist
Aerojet Rocketdyne downgraded to Hold from Buy at Truist
RP RealPage
$87.27 /

+19.63 (+29.02%)

12/22/20 JMP Securities
RealPage price target raised to $101 from $80 at JMP Securities
12/22/20 Baird
RealPage downgraded to Neutral from Outperform at Baird
12/21/20 BMO Capital
RealPage downgraded to Market Perform from Outperform at BMO Capital
12/21/20 RBC Capital
RealPage downgraded to Sector Perform from Outperform at RBC Capital
NKE Nike
$143.97 /

+4.93 (+3.55%)

12/22/20 Argus
Nike price target raised to $165 from $140 at Argus
12/21/20 Jefferies
Nike price target raised to $140 from $117 at Jefferies
12/21/20 Baird
Nike near-term estimate upside limited, says Baird
12/21/20 Raymond James
Nike price target raised to $155 from $140 at Raymond James
WBAI 500.com
$3.79 /

+1.135 (+42.75%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

07/08/20
Fly Intel: Top five analyst initiations
07/08/20 Piper Sandler
NantKwest initiated with an Overweight at Piper Sandler
QURE uniQure
$38.51 /

-7.39 (-16.10%)

12/22/20 Jefferies
uniQure's EtranaDez unlikely to raise HCC risk in hemB patients, says Jefferies
12/22/20 RBC Capital
uniQure price target lowered to $53 from $61 at RBC Capital
12/22/20 H.C. Wainwright
uniQure price target lowered to $80 from $85 at H.C. Wainwright
12/21/20 Stifel
AMT-061 clinical hold 'obviously negative,' implications less clear, says Stifel
FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

12/21/20 Mizuho
FibroGen should be bought on PDUFA extension weakness, says Mizuho
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
RP RealPage
$87.27 /

+19.63 (+29.02%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

  • 23
    Jul
  • 25
    Jun
  • 20
    May
  • 19
    May
  • 12
    Feb
  • 06
    Feb
QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

RP RealPage
$87.27 /

+19.63 (+29.02%)

QURE uniQure
$38.51 /

-7.39 (-16.10%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

LMT Lockheed Martin
$349.32 /

-6.91 (-1.94%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

AJRD Aerojet Rocketdyne
$52.78 /

+10.65 (+25.28%)

PFE Pfizer
$37.37 /

-0.315 (-0.84%)

NKE Nike
$143.97 /

+4.93 (+3.55%)

NK NantKwest
$16.02 /

+5.78 (+56.45%)

MRNA Moderna
$138.24 /

-1.99 (-1.42%)

FGEN FibroGen
$40.01 /

-3.98 (-9.05%)

BNTX BioNTech
$106.36 /

+2.27 (+2.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.